Pangen Biotech Inc. Logo

Pangen Biotech Inc.

Develops and manufactures biopharmaceuticals and offers CDMO services.

222110 | KO

Overview

Corporate Details

ISIN(s):
KR7222110009
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 신원로 306, 2동 4층(원천동 영통이노플렉스) , 수원시

Description

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-08-24 00:00
주식등의대량보유상황보고서(일반)
Korean 108.2 KB
2020-08-13 00:00
반기보고서 (2020.06)
Korean 957.5 KB
2020-08-12 00:00
단일판매ㆍ공급계약체결
Korean 9.9 KB
2020-08-10 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 19.4 KB
2020-08-06 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 13.5 KB
2020-07-20 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 31.3 KB
2020-07-20 00:00
주식등의대량보유상황보고서(일반)
Korean 103.0 KB
2020-07-15 00:00
단일판매ㆍ공급계약체결
Korean 10.0 KB
2020-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 19.4 KB
2020-06-22 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 31.3 KB
2020-06-22 00:00
주식등의대량보유상황보고서(일반)
Korean 92.3 KB
2020-05-13 00:00
[기재정정]사업보고서 (2019.12)
Korean 1.1 MB
2020-05-13 00:00
분기보고서 (2020.03)
Korean 962.1 KB
2020-05-12 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 15.0 KB
2020-05-11 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 31.3 KB

Automate Your Workflow. Get a real-time feed of all Pangen Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pangen Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pangen Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.